Loading stock data…
REGENXBIO Inc. (RGNX)
$8.76-0.18 (-2.01%)
Market ClosedLast close Sep 8
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
REGENXBIO Inc. in the Healthcare sector is trading at $8.76 with a market capitalization of $711M. Wall Street consensus targets $23.73 (11 analysts), implying a +170.9% move over the next 12 months. The stock is currently 46% below its 52-week high of $16.19, remaining 15.0% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +170.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $108.02M↑ | $6.39M↓ | $30.34M↑ | $29.73M↑ | $21.36M |
| Gross Profit | $106.98M↑ | -$4.68M↓ | $24.41M↑ | $24.01M↑ | $16.15M |
| Operating Income | $29.26M↑ | -$83.36M↓ | -$57.64M↓ | -$52.41M↑ | -$63.28M |
| Net Income | $22.71M↑ | -$90.05M↓ | -$67.15M↓ | -$61.94M↑ | -$70.87M |
Peer Comparison
JNJUNHPFE
Fundamentals
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$710.63M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.94
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-273.72%
Volume
Today's trading volume
998,056
Recent News
Regenxbio’s Gene Therapy Faces Another FDA Setback in Hunter Syndrome
Regenxbio Inc. (NASDAQ:RGNX) suffered another setback in its effort to bring RGX-121 to patients with Hunter syndrome. The FDA placed the experimental gene therapy on clinical hold after spinal scans identified abnormalities in five treated participants, and Reuters reported that Regenxbio shares fell more than 24% in premarket trading following the announcement. The findings add […]
Regenxbio’s RGX-121 Setback Carries A Potential Cash Risk, Warns Clear Street
Clear Street said the FDA decision would significantly delay Regenxbio’s resubmission of its application and a potential voucher that could bring in additional cash.
FDA places clinical hold on REGENXBIO’s RGX-121 in MPS II trial
The update follows the detection of asymptomatic findings in the spine MRIs of five participants enrolled in the CAMPSIITE study.
Sector Update: Healthcare Stocks Softer Late Afternoon
Healthcare stocks decreased late Monday afternoon, with the NYSE Healthcare Index and the State Stre
RGNX Stock On Track For Worst Day In Over Three Months — BofA Says Buy Despite ‘Disappointing’ FDA Hold On Gene Therapy
BofA called the clinical hold on RGX-121 disappointing and a reversal of July’s progress but kept a $15 price target on the stock.